188 related articles for article (PubMed ID: 19888521)
1. Structural features of low-molecular-weight heparins affecting their affinity to antithrombin.
Bisio A; Vecchietti D; Citterio L; Guerrini M; Raman R; Bertini S; Eisele G; Naggi A; Sasisekharan R; Torri G
Thromb Haemost; 2009 Nov; 102(5):865-73. PubMed ID: 19888521
[TBL] [Abstract][Full Text] [Related]
2. Structural features of glycol-split low-molecular-weight heparins and their heparin lyase generated fragments.
Alekseeva A; Casu B; Cassinelli G; Guerrini M; Torri G; Naggi A
Anal Bioanal Chem; 2014 Jan; 406(1):249-65. PubMed ID: 24253408
[TBL] [Abstract][Full Text] [Related]
3. Antithrombin III-Binding Site Analysis of Low-Molecular-Weight Heparin Fractions.
Chen Y; Zhao J; Yu Y; Liu X; Lin L; Zhang F; Linhardt RJ
J Pharm Sci; 2018 May; 107(5):1290-1295. PubMed ID: 29339133
[TBL] [Abstract][Full Text] [Related]
4. Antithrombin binding of low molecular weight heparins and inhibition of factor Xa.
Lin P; Sinha U; Betz A
Biochim Biophys Acta; 2001 Apr; 1526(1):105-13. PubMed ID: 11287128
[TBL] [Abstract][Full Text] [Related]
5. Affinity capillary electrophoresis for the determination of binding affinities for low molecular weight heparins and antithrombin-III.
Dinges MM; Solakyildirim K; Larive CK
Electrophoresis; 2014 May; 35(10):1469-77. PubMed ID: 24616065
[TBL] [Abstract][Full Text] [Related]
6. Screening enoxaparin tetrasaccharide SEC fractions for 3-O-sulfo-N-sulfoglucosamine residues using [(1)H,(15)N] HSQC NMR.
Beecher CN; Manighalam MS; Nwachuku AF; Larive CK
Anal Bioanal Chem; 2016 Feb; 408(6):1545-55. PubMed ID: 26758598
[TBL] [Abstract][Full Text] [Related]
7. Antithrombin-binding octasaccharides and role of extensions of the active pentasaccharide sequence in the specificity and strength of interaction. Evidence for very high affinity induced by an unusual glucuronic acid residue.
Guerrini M; Guglieri S; Casu B; Torri G; Mourier P; Boudier C; Viskov C
J Biol Chem; 2008 Sep; 283(39):26662-75. PubMed ID: 18640975
[TBL] [Abstract][Full Text] [Related]
8. Differentiation of the low-molecular-weight heparins.
Racine E
Pharmacotherapy; 2001 Jun; 21(6 Pt 2):62S-70S; discussion 71S-72S. PubMed ID: 11401195
[TBL] [Abstract][Full Text] [Related]
9. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
Brieger D; Dawes J
Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
[TBL] [Abstract][Full Text] [Related]
10. Determination of the molecular weight of low-molecular-weight heparins by using high-pressure size exclusion chromatography on line with a triple detector array and conventional methods.
Bisio A; Mantegazza A; Vecchietti D; Bensi D; Coppa A; Torri G; Bertini S
Molecules; 2015 Mar; 20(3):5085-98. PubMed ID: 25808152
[TBL] [Abstract][Full Text] [Related]
11. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
12. Fragment profiling of low molecular weight heparins using reversed phase ion pair liquid chromatography-electrospray mass spectrometry.
Xu X; Li D; Chi L; Du X; Bai X; Chi L
Carbohydr Res; 2015 Apr; 407():26-33. PubMed ID: 25701653
[TBL] [Abstract][Full Text] [Related]
13. Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy.
Guerrini M; Guglieri S; Naggi A; Sasisekharan R; Torri G
Semin Thromb Hemost; 2007 Jul; 33(5):478-87. PubMed ID: 17629844
[TBL] [Abstract][Full Text] [Related]
14. Quantitative analysis of antithrombin III binding site in low molecular weight heparins by exhausetive heparinases digestion and capillary electrophoresis.
Zhang M; Li G; Zhang Y; Kang J
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Nov; 1068-1069():78-83. PubMed ID: 29031112
[TBL] [Abstract][Full Text] [Related]
15. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
16. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
17. [Determination of sulfation degree of heparin and low molecular weight heparins by capillary electrophoresis].
Shen Y; Kang J
Se Pu; 2020 Oct; 38(10):1238-1242. PubMed ID: 34213122
[TBL] [Abstract][Full Text] [Related]
18. Isolation of a pure octadecasaccharide with antithrombin activity from an ultra-low-molecular-weight heparin.
Mourier PA; Guichard OY; Herman F; Viskov C
Anal Biochem; 2014 May; 453():7-15. PubMed ID: 24561026
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of UH and LMWH are similar with respect to antithrombin activity.
Morris TA; Jacobson A; Marsh JJ; Lane JR
Thromb Res; 2005; 115(1-2):45-51. PubMed ID: 15567452
[TBL] [Abstract][Full Text] [Related]
20. Analytical comparison of a US generic enoxaparin with the originator product: The focus on comparative assessment of antithrombin-binding components.
Mourier PAJ; Herman F; Sizun P; Viskov C
J Pharm Biomed Anal; 2016 Sep; 129():542-550. PubMed ID: 27497655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
